Pharmaceutical companies are becoming more selective about the external assets and partnerships they bring into their pipelines. For biotechnology companies, that selectivity makes access to informed counterparties increasingly important. BioPharma Deals 2026 will bring senior business development and licensing professionals to Munich on November 24 and 25 for discussions centered on transactions across the life sciences sector.
The summit will take place at the Science Congress Center Munich and is designed for professionals from pharmaceutical and biotechnology companies alongside investors and service providers. Its focus includes licensing and alliances as well as mergers and acquisitions, co-development and external innovation.
Licensing decisions will be central to the program. Companies evaluating external assets must consider scientific fit alongside development strategy and commercial objectives. The summit will provide a setting for participants to examine these considerations through executive discussions and company presentations, giving potential counterparties an opportunity to assess opportunities before entering detailed negotiations.
One-to-one partnering will provide a more focused route into those conversations. More than 500 structured meetings are expected across the two-day summit, with registered participants able to review profiles and request meetings in advance. The format is intended to connect organizations according to specific partnering interests rather than relying solely on informal conference networking.
Corporate development will add another layer to the discussions. M&A professionals and advisors will examine transactions involving pharmaceutical and biotechnology businesses, while alliance management and external innovation leaders will address how partnerships can be structured after an agreement is reached. These discussions place deal-making within broader portfolio and growth strategies.
The event’s intentionally focused format also reflects the specialized nature of life sciences transactions. BioPharma Deals describes its audience as senior BD&L decision-makers, including business development leaders, corporate strategy executives, biotech and pharma CEOs and investment professionals.
CIO Applications is serving as a media partner because BioPharma Deals intersects with its coverage of enterprise technology, artificial intelligence and business transformation across industries. The publication focuses on practical technology and strategic decision-making for CIOs, CTOs and enterprise leaders. Editorial coverage can extend the Munich discussions by examining how digital intelligence, data systems and emerging technologies influence investment evaluation and strategic decisions within life sciences.
The biopharma deal environment increasingly depends on disciplined evaluation rather than transaction volume alone. BioPharma Deals 2026 provides a concentrated setting for examining how licensing, investment and strategic partnerships can connect scientific opportunities with the business capabilities required to advance them.
